PMID- 37121695
OWN - NLM
STAT- MEDLINE
DCOM- 20230502
LR  - 20230502
IS  - 1347-5215 (Electronic)
IS  - 0918-6158 (Linking)
VI  - 46
IP  - 5
DP  - 2023
TI  - Combination Therapy with Betamethasone and Josamycin Demonstrates Superior 
      Therapeutic Efficacy in an NC/Nga Mouse Model of Atopic Dermatitis.
PG  - 693-699
LID - 10.1248/bpb.b22-00781 [doi]
AB  - We have previously demonstrated the excellent bactericidal activity of josamycin 
      against Staphylococcus aureus isolated from patients with atopic dermatitis (AD), 
      with therapeutic efficacy equal to that of betamethasone. The present study was 
      designed to evaluate the effectiveness of combination therapy with betamethasone 
      and josamycin for AD. Betametasone (0.1%) and josamycin (0.1%) were topically 
      administered to NC/Nga mice with severe AD-like skin lesions. Skin severity 
      scores, histological changes in skin lesions, and serum immunoglobulin E (IgE) 
      levels were assessed as indicators of therapeutic efficacy. Topical treatment 
      with both drugs suppressed the skin severity score to a greater degree than 
      betamethasone alone. This was associated with a reduction of epidermal 
      thickening, a reduced density of dermal cellular infiltration, a decreased mast 
      cell count in the dermis, and a reduced serum IgE level. In addition, both drugs 
      in combination markedly reduced the expression of interferon (IFN)-gamma and 
      interleukin (IL)-4 in auricular lymph node cells, as well as the S. aureus count 
      on the lesioned skin. These results show that simultaneous topical application of 
      both drugs can ameliorate severe AD-like skin lesions in NC/Nga mice. It is 
      suggested that combination therapy with betamethasone and josamycin would be 
      beneficial for control of severe AD lesions colonized by S. aureus by inhibiting 
      the development of both T helper (Th) type 1 (Th1) and Th2 cells and also through 
      elimination of superficially located S. aureus.
FAU - Matsui, Katsuhiko
AU  - Matsui K
AD  - Department of Clinical Immunology, Meiji Pharmaceutical University.
FAU - Muranaka, Madoka
AU  - Muranaka M
AD  - Department of Clinical Immunology, Meiji Pharmaceutical University.
FAU - Yamaguchi, Tomoka
AU  - Yamaguchi T
AD  - Department of Clinical Immunology, Meiji Pharmaceutical University.
FAU - Maeda, Manami
AU  - Maeda M
AD  - Department of Clinical Immunology, Meiji Pharmaceutical University.
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Biol Pharm Bull
JT  - Biological & pharmaceutical bulletin
JID - 9311984
RN  - HV13HFS217 (Josamycin)
RN  - 9842X06Q6M (Betamethasone)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Mice
MH  - Animals
MH  - *Dermatitis, Atopic/drug therapy/pathology
MH  - Josamycin/therapeutic use
MH  - Betamethasone/therapeutic use
MH  - Staphylococcus aureus
MH  - Skin/pathology
MH  - Disease Models, Animal
MH  - Immunoglobulin E
OTO - NOTNLM
OT  - Staphylococcus aureus
OT  - atopic dermatitis
OT  - betamethasone
OT  - josamycin
EDAT- 2023/05/01 00:42
MHDA- 2023/05/02 06:42
CRDT- 2023/04/30 21:23
PHST- 2023/05/02 06:42 [medline]
PHST- 2023/05/01 00:42 [pubmed]
PHST- 2023/04/30 21:23 [entrez]
AID - 10.1248/bpb.b22-00781 [doi]
PST - ppublish
SO  - Biol Pharm Bull. 2023;46(5):693-699. doi: 10.1248/bpb.b22-00781.